Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Pyxis Oncology (NASDAQ:PYXS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

PYXS has been the subject of a number of other reports. HC Wainwright raised their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Stephens increased their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Royal Bank Of Canada lowered their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.67 on Friday. The firm has a market cap of $103.97 million, a P/E ratio of -1.04 and a beta of 1.45. The firm’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $2.51. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. Catalyst Funds Management Pty Ltd bought a new position in Pyxis Oncology in the second quarter valued at approximately $26,000. Dimensional Fund Advisors LP boosted its position in Pyxis Oncology by 37.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock valued at $58,000 after purchasing an additional 13,550 shares during the last quarter. HRT Financial LP increased its position in shares of Pyxis Oncology by 157.5% during the 4th quarter. HRT Financial LP now owns 39,649 shares of the company’s stock worth $45,000 after purchasing an additional 24,251 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $40,000. Finally, LPL Financial LLC raised its stake in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after purchasing an additional 21,100 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.